New Whole Animal ELISA for Angiogenic Drug Screening

用于血管生成药物筛选的新型全动物 ELISA

• 批准号: 7541282
• 负责人: WEN L SENG
• 金额: $ 13.52万
• 依托单位: PHYLONIX PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7541282
• 关键词: Aftercare; Angioblast; Angiogenesis Inhibitors; Animal Model; Animal Testing; Animals; Binding; Biological; Biological Assay; Biological Process; Biological Products; Body measure procedure; Cell Proliferation; Cells; Chemical Structure; Clinical Services; Clinical Trials; Collection; Comparative Study; Complex; Condition; Contracts; Cyclin-Dependent Kinase Inhibitor; Data; Development; Diabetes Mellitus; Diabetic Retinopathy; Disease; Disruption; Drug Delivery Systems; Endothelial Cells; Environment; Enzyme-Linked Immunosorbent Assay; Evaluation; Exhibits; Genetic; Genistein; Germany; Goals; Government; Heart Diseases; Homologous Gene; Human; Impaired wound healing; Lead; Length; Libraries; Macular degeneration; Malignant Neoplasms; Mammals; Modeling; Modification; Monoclonal Antibodies; Morphology; Myocardial Ischemia; Numbers; Pattern; Performance; Peripheral arterial disease; Personal Satisfaction; Persons; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phosphotransferases; Physiological; Preclinical Drug Evaluation; Procedures; Process; Property; Provider; Public Health; Purpose; Reagent; Reproducibility; Research; Rivers; SU 5416; Sampling; Screening procedure; Services; Signal Transduction; Site; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Staining method; Stains; Tertiary Protein Structure; Therapeutic; Tyrosine Kinase Inhibitor; Vascular Endothelial Growth Factor Receptor; Visual; Zebrafish; angiogenesis; base; chorioallantoic membrane; drug development; flavopiridol; high throughput screening; in vivo; in vivo Bioassay; instrumentation; kinase inhibitor; pre-clinical; predictive modeling; programs; research clinical testing

DESCRIPTION (provided by applicant): The overall goal of this research is to develop a rapid, quantitative in vivo assay format for screening angiogenic drug candidates using zebrafish as a model organism. Angiogenesis is well established as a major biological process involved in several pathological conditions, including cancer, diabetic retinopathy, macular degeneration, ischemic heart disease, peripheral arterial disease, and impaired wound healing. However, the lack of understanding of the biological basis of angiogenesis and the lack of assays and animal models have hampered drug development. A significant advantage of the proposed zebrafish assay is that the therapeutic potential of a compound is evaluated in a complex physiological environment with much higher throughput than mammalian in vivo bioassays. Using cell-based screens, this information is impossible to obtain. PUBLIC HEALTH RELEVANCE: Angiogenesis has been shown to be involved in several serious diseases, including diabetes, cancer, heart disease and macular degeneration. This SBIR aims to develop a high throughput quantitative in vivo zebrafish microplate based assay for evaluating angiogenic effects of potential therapeutics.

描述（由申请人提供）：本研究的总体目标是开发一种快速、定量的体内试验形式，用于使用斑马鱼作为模式生物筛选血管生成候选药物。血管生成被公认为涉及多种病理状况的主要生物学过程，包括癌症、糖尿病性视网膜病变、黄斑变性、缺血性心脏病、外周动脉疾病和受损的伤口愈合。然而，缺乏对血管生成的生物学基础的理解以及缺乏测定和动物模型阻碍了药物开发。所提出的斑马鱼测定法的显著优点是，在复杂的生理环境中以比哺乳动物体内生物测定高得多的通量评价化合物的治疗潜力。使用基于细胞的屏幕，这些信息是不可能获得的。公共卫生相关性：血管生成已被证明与几种严重疾病有关，包括糖尿病、癌症、心脏病和黄斑变性。该SBIR旨在开发一种基于斑马鱼微板的高通量定量体内试验，用于评估潜在治疗药物的血管生成作用。